|
|
Flucloxacillin
Paul A. Pham Pharm.D.
04-01-2008
-
Available formulation in Zambia: Capsules: 250mg, 500mg; Syrup: 125mg/5mL, 250mg/5mL; combination capsule: 500mg: 250 mg amoxycillin and 250 mg flucloxacillin; combination syrup: 125mg amoxycillin and 125 mg flucloxacillin
- Cellulitis: flucloxacillin 500 mg PO q6h (1 hour before meals).
Zambia Information Author: Paul A. Pham, Pharm.D.
- Skin and soft tissue infections
- Otitis media
- UTI
- Respiratory tract infections (pharyngitis and pneumonia)
- Staphylococcal infections (MSSA)
- Streptococcal infections
- Usual adult dose: 250-500 mg PO q6h (1 hr before meals).
- Severe infections: up to 8 gm per day in 6 divided doses 1 hr before meals.
Usual dose
Usual dose
Consider dose reduction
No significantly removed in HD. No supplemental dose needed.
No significantly removed in PD. No supplemental dose needed.
No data.
- Generally well tolerated.
- Hypersensitivity reactions and rash
- Drug fever
- Coombs' test positive without hemolytic anemia
- Hepatitis and cholestatic jaundice
- GI intolerance and diarrhea
- Herxheimer reaction (with treatment of spirochetal infections)
-
C. difficile-associated colitis
- Interstitial nephritis
- Hypernatremia (floxacillin sodium has 2.2 mmol of sodium per gram)
-
Tetracyclines: in vitro antagonism when co-administered. Bactericidal effect of penicillins may be diminished in vivo. Avoid co-administration.
- Probenecid: increases floxacillin serum concentrations with co-administration. Unlikely to be clinically significant in pts with normal renal function.
- Flucloxacillin has twice the bioavailability compared to oral cloxacillin, but is not available in the U.S.
- Similar pharmacokinetic parameters when compared to dicloxacillin.
|
|
![Johns Hopkins POC-IT: Point of Care Information Technology [Home]](../../images/pocit_logo.gif){kind=logo}
Help
